Metabolic Tumor Volume as a Prognostic Imaging-Based Biomarker for Head and Neck Cancer—Pilot Results from RTOG 0522

David L. Schwartz, MD[*], **Jonathan Harris, MS**[^], **Min Yao, MD, PhD**[#], **David I. Rosenthal, MD, FACR**[+], **Adam Opanowski, CNMT, PET, NCT, RT (N)**[¶], **Anthony Levering, RT (R)(CT)(MR), CIIP**[¶], **K. Kian Ang, MD, PhD**[+], **Andy M. Trotti, MD**[§], **Adam S. Garden, MD, FASTRO**[+], **Christopher U. Jones, MD, FACR**[∨], **Paul Harari, MD**[⌐], **Robert Foote, MD, FASTRO**[=], **John Holland, MD**[α], **Qiang Zhang, MD, PhD**[^], and **Quynh-Thu Le, MD, FASTRO**[╫]

[*]Department of Radiation Oncology, U.T. Southwestern School of Medicine, Dallas, TX

[^]RTOG Statistics Office, Philadelphia, PA

[#]Department of Radiation Oncology, Case Western Reserve University School of Medicine, Cleveland, OH

[+]Department of Radiation Oncology, U.T. MD Anderson Cancer Center, Houston, TX

[¶]American College of Radiology Imaging Network, Philadelphia, PA

[§]Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL

[∨]Sutter Medical Group, Sacramento, CA

[⌐]Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI

[=]Department of Radiation Oncology, Mayo Clinic, Rochester, MN

[α]Department of Radiation Medicine, Oregon Health and Science University, Portland, OR

[╫]Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, CA

Abstract

Purpose—To evaluate candidate FDG-PET/CT imaging biomarkers for head and neck chemoradiotherapy outcomes in the cooperative group trial setting.

Address Correspondence to: David L. Schwartz, MD, Department of Radiation Oncology, Harold C. Simmons Comprehensive Cancer Center, U.T. Southwestern School of Medicine, 5801 Forest Park Road, Dallas, TX 75390, Voice: 214-645-8525, Fax: 214-645-8526, david.schwartz@utsw.edu.

Methods—RTOG 0522 patients consenting to a secondary FDG-PET/CT sub-study were serially imaged at baseline and 8 weeks following radiation. Maximum standardized uptake value (SUVmax), SUV peak (mean SUV within a 1 cm sphere centered on SUVmax), and metabolic tumor volume (MTV) using 40% of SUVmax as threshold were obtained from primary tumor and involved nodes.

Results—Out of 940 patients entered onto RTOG 0522, 74 were analyzable for this sub-study. Neither high baseline SUVmax nor SUVpeak from primary or nodal disease were associated with poor treatment outcomes. However, primary tumor MTV above the cohort median was associated with worse LRC (HR 4.01, 95% CI [1.28, 12.52], p = 0.02) and PFS (HR 2.34, 95% CI [1.02, 5.37], p = 0.05). Although MTV and T stage appeared to correlate (mean MTV 6.4, 13.2, 26.8 for T2, T3, and T4 tumors, respectively), MTV remained a strong independent prognostic factor for PFS in bivariate analysis that included T stage. Primary MTV remained prognostic in p16-associated oropharyngeal cancer cases, although sample size was limited.

Conclusion—High baseline primary tumor MTV was associated with worse treatment outcomes in this limited patient subset of RTOG 0522. Additional confirmatory work will be required to validate primary tumor MTV as a prognostic imaging biomarker for patient stratification in future trials.

INTRODUCTION

Effective patient selection drives successful clinical cancer trial design. Tissue-based biomarkers have been used towards this end, with a promise to increase study power and reduce treatment development costs. However, tumor tissue collection is expensive and burdensome. Tumor imaging provides an alternative means to non-invasively define disease phenotype and treatment response.

Functional imaging delivers quantitative characterization of tumor and host tissue physiology. FDG-PET, with or without co-registered CT, serves as the traditional workhorse for functional head and neck imaging. Published experience with FDG-PET- defined staging is mature, and has been summarized by meta-analyses (1), expert consensus reports (2, 3), and comparative effectiveness studies (4). FDG-PET incrementally improves staging accuracy and treatment response assessment over anatomic imaging (5–8), particularly if guided by complementary clinical features (9, 10). Some institutional series suggest that certain FDG-PET parameters, such as the maximum or peak standardized uptake values (SUV), may serve as quantifiable imaging biomarkers for radiotherapy outcomes (11–13). However, conflicting reports refute the predictive value of SUV (14), and quantitative head and neck FDG-PET outcome measures remain untested in the cooperative group trial setting.

RTOG 0522 recently completed enrollment of 940 patients diagnosed with locally advanced head and neck cancer. Study subjects received concurrent radiation therapy and cisplatin, with or without the addition of cetuximab. All RTOG 0522 subjects with N2-3 disease (with the exception of N2c with both sides   N1) were eligible for baseline and post-treatment co-registered PET/CT imaging analysis. Predefined study objectives included correlation of pre- and post-treatment PET/CT scan findings with histologic findings of neck dissection

specimens and treatment outcomes. Given interval publication of encouraging institutional pilot findings for use of FDG-PET-defined metabolic tumor volume (MTV) as an imaging biomarker for radiotherapy treatment response and tumor control outcomes (15–17), MTV was included as a secondary post-hoc study objective in this current report.

METHODS

Study Population

Patients enrolled to RTOG 0522 with N2a, N2b, N2c (with right and/or left side N2a-N2b), or N3 disease, who agreed to participate in the PET/CT study, and for whom at least one PET image set was available for central review were included in this analysis.

PET/CT Image and Scanner Compatibility Requirements

All centers participating in this imaging study had to provide one test case to the ACRIN PET Core Lab prior to start of enrollment to credential their file transfer capabilities and image quality. The PET Core Lab provided software for imaging facilities to collect, de-identify, and submit image sets either from a PET/CT scanner or a PACS system to the ACRIN image archive. All imaging had to be performed on a combined PET/CT instrument with full ring PET and four-slice or greater multi-detector CT operating in high-sensitivity 2D mode, if available. To simplify multi-institutional participation, centers were not required to use uniform PET-CT software. 3D mode was permissible for patients imaged on combined PET/CT scanners without a 2D mode.

Patient Preparation and FDG Injection

Participating centers were instructed to record patient height and weight prior to each PET scan, to have patients observe a four to six-hour fasting period prior to FDG injection, and to measure serum glucose concentration prior to scanning. A serum glucose value less than 200 mg/dL was necessary to proceed to imaging. Centers were instructed to inject a dose of 10–20 mCi of FDG intravenously and to begin imaging within 50–70 minutes following tracer administration.

Baseline and Post-Treatment PET/CT Imaging

Imaging was required to encompass the vertex of the head down through the entire pelvis. The recommended imaging protocol incorporated two discrete phases: during the first phase, head and neck scanning was performed with arms resting at sides and full neck extension using a 120 keV/300 mA, 0.5-second detector rotation time ("high mA") CT scan with intravenous contrast (100 cc contrast bolus administered at 1.5 cc/second, with a 50 second scan delay and with the scan started inferiorly, moving cranially), followed by a 120 keV/80 mA, 0.8-second detector rotation time ("low mA") CT scan for PET attenuation correction, followed lastly by PET scanning. Standard manufacturer recommendations for specific low and high mA CT scanning parameters could be substituted. Two fields of view (approximately 15 cm) were required for full head and neck PET imaging from manubrium to vertex. Centers were instructed to allow patients to rest their neck for 1–2 minutes. For the second phase of imaging, the neck was shifted into neutral position, and the remainder of the body was surveyed per routine local institutional protocol with arms raised above the

head to allow for thoracic and abdominal imaging. At least four to five PET fields of view were to be used for this phase. PET data were corrected for dead time, scatter, random coincidence events and attenuation, and ultimately reconstructed into images via the filtering algorithm provided by the scanner manufacturer. A post-treatment FDG-PET/CT scan was recommended 8–9 weeks following completion of treatment (in addition to mandatory CT or MR post-treatment imaging). Centers were requested to perform post-treatment PET/CT imaging in this time frame and on the same scanner, if possible.

Maximum Standardized Uptake Value (SUVmax), Peak SUV (SUVpeak), and Metabolic Tumor Volume (MTV)

SUV normalized by specific injected dose and patient weight was calculated on centralized review by two head and neck radiation oncologists with specific expertise in PET-CT interpretation (DLS and MY) employing commercial image analysis software (MIM Software, v.5.2, Cleveland, OH). Detection of primary and nodal disease by FDG-PET/CT was determined qualitatively as FDG uptake greater than surrounding normal soft tissue within a CT-delineated anatomic (primary disease or nodal) abnormality. SUVmax was defined as (tissue activity) (μCi/ml)/(injected dose (mCi)/(patient weight [kg]) within the voxel having the highest activity within a given region of interest (ROI). These values were determined separately for ROIs within primary tumor and involved cervical lymph nodes. Each ROI had to encompass the entire FDG-avid lesion of interest, with boundaries guided by CT delineation. SUVpeak for primary and nodal disease was measured from a 1 cubic centimeter sphere centered on the voxel with the highest mean SUV value. The location of this sphere was manually checked to assure reasonable position within disease. Primary tumor MTV contours were generated from voxels that were equal to or greater than 40% of primary SUVmax. A specific tumor can have a much higher SUV than another tumor, but MTV calculations and volume generation will remain consistent across tumors since the analysis tool performs identical calculations of proportionality regardless of baseline SUVmax value. Nodal MTV was measured separately for each side of the neck, inclusive of all metabolically active nodes (including cystic regions within these nodes), and defined as the nodal tumor volume above 40% of the nodal SUVmax. For bilateral neck disease, the maximum of right and left sides was used for SUV and the sum for MTV. Total MTV, defined as primary MTV plus nodal MTV, was calculated for patients with both measures.

Data Analysis and Statistics

The following pre- and post-treatment PET values were obtained from central review: SUVmax, SUVpeak, and MTV of the primary tumor, right nodal disease, and left nodal disease. The protocol analysis plan pre-specified the analysis of SUV measures. Evaluation of MTV represents post-hoc secondary analysis, and must be formally considered exploratory in nature. The study cohort was dichotomized into equal size comparator groups by median PET values to maximize statistical power for analysis. Patients with at least one readable value from either reader were included. Consistency between readers was measured by intraclass correlation coefficient.

Clinical endpoints specified by the trial protocol were local relapse (including salvage surgery for primary site with tumor present/unknown), regional relapse (including neck

dissection > 15 weeks after the end of radiation therapy with tumor present/unknown), local-regional relapse, distant metastasis, progression-free survival, and overall survival. Only death was considered a competing risk for local relapse, regional relapse, local-regional relapse, or distant metastasis. Progression-free survival events were defined as local or regional relapse, distant metastasis, or death due to any cause. All endpoints were measured from the date of randomization. Rates for local, regional, and local-regional relapse, and distant metastasis were estimated by the cumulative incidence method (18), and rates for progression-free and overall survival were estimated by the Kaplan-Meier method (19). Hazard ratios were estimated by Cox proportional hazards models (20). To address whether negative (SUVmax < 3, per Yao, et. al. (21)) post-treatment PET/CT in patients who achieve a clinical complete nodal response (CR, defined as no evidence of nodal disease on physical exam and/or imaging) predicts for a low nodal relapse rate (< 10%) at 2 years, the 2-year regional relapse rates in 4 groups were calculated: (1) clinical CR, negative PET; (2) clinical <CR, negative PET; (3) clinical CR, positive PET; (4) clinical <CR, positive PET.

Exploratory post-hoc subgroup analysis was performed to selectively evaluate PET measures in patients with p16-positive oropharyngeal cancer. Missing p16 values were imputed 20 times using conditional model specification for multivariate imputation via Gibbs sampling (22), and the resulting datasets were combined using Rubin's formula (23), and sensitivity analyses were conducted to validate the robustness of the imputation procedure. Akaike information criterion (AIC) (24) was used to measure the relative quality of our statistical models.

RESULTS

Imaging Study Cohort

One-hundred sixteen patients agreed to participate in the PET/CT study. Forty-two subjects did not follow through with post-treatment imaging or had unreadable image files, yielding 74 patients from 19 centers with both pre- and post-treatment PET/CT imaging available for this analysis. In addition, 535 patients were eligible for the PET/CT study based on N stage but chose not to participate, for a total of 577 patients not included in this analysis. Analyzed patients enjoyed better performance status and shorter pack-year tobacco exposure, but presented at a more advanced T stage than excluded patients (Table 1). At the time of analysis, median follow-up for surviving patients (58 of 74) was 4.2 years (range, 3.1 to 6.2).

PET Summary and Reviewer Agreement

Summary FDG-PET/CT outcome measures are listed in Table 2. Reader agreement was excellent (intraclass correlation coefficient 0.80) for all measurements, except for post-treatment nodal SUVpeak values (0.51–0.59). Low post-treatment SUV values made thresholding for MTV calculation difficult to reproduce; thus, post-treatment MTVs were not tabulated.

Correlation of Baseline SUV Values with Treatment Outcomes

Elevated baseline primary/nodal FDG SUVmax or SUVpeak values above median value of the study cohort were not associated with poor clinical outcomes (Table 3). This also held true when either value was alternatively analyzed as a continuous variable (data not shown).

Correlation of Post-Treatment SUV Values with Nodal Response

The 2-year nodal relapse rates were: 3.9% (95% CI: 0.0, 11.4) in patients with clinical CR, negative PET; 33.3% (95% CI: 8.4, 58.2) in clinical <CR, negative PET; 16.7% (95% CI: 0.0, 38.8) in clinical CR, positive PET; and 11.1% (95% CI: 0.0, 33.1) in clinical <CR, positive PET. There were only 10 nodal relapses across these 4 groups, and differences were not statistically significant (p=0.15).

Correlation of Baseline MTV with Treatment Outcomes

Pretreatment primary MTV above the study cohort median was associated with local-regional relapse (hazard ratio 4.01, 95% CI [1.28, 12.52], p=0.02) and poorer progression-free survival (hazard ratio 2.34, 95% CI [1.02, 5.37], p=0.05) (Table 4, Figure 1). Elevated baseline nodal MTV values, on the other hand, were non-prognostic. Results for combined primary and nodal MTV were similar to primary MTV alone (hazard ratio for progression-free survival 2.37, 95% CI [0.99, 5.69], p=0.05). Primary MTV and total MTV were highly correlated (Spearman correlation 0.78 on the raw values; phi coefficient 0.57 for measures dichotomized by group median).

Supplementary Table 1 presents summary statistics for primary MTV by T stage. The mean primary MTV roughly doubled with each upstage: T2 6.39, T3 13.24, T4, 26.79. Primary MTV was a stronger prognostic factor than T stage for local-regional relapse and progression-free survival (Table 5). The hazard ratios for primary MTV changed little when T stage was added to a bivariate model, but T stage lost much of its prognostic value for local-regional relapse, and all for progression-free survival, when primary MTV was added to the model. Akaike information criterion (AIC) is lowest when primary MTV remained as a single variable in the model. Collinearity was not an issue, with the variance inflation factor limited to 1.27.

Subgroup Analysis for p16-Positive Oropharynx Cases

Primary MTV and total MTV remained prognostic in patients with p16-associated oropharyngeal cancer (Supplementary Table 2). This ability was associated exclusively with MTV; SUVmax and SUVpeak remained non-prognostic.

DISCUSSION

A mixed picture has emerged regarding utility of FDG-PET-derived imaging biomarkers in head and neck cancer. Although older series suggest poor outcomes in patients presenting with highly elevated SUV values (11–13), prospective institutional data (14) suggest that baseline SUVmax and SUVpeak values are not prognostic, either in unselected patients or in patients with HPV-associated oropharyngeal disease. In fact, our current results from RTOG 0522 alternatively suggest better locoregional control and progression-free survival in

patients presenting with primary SUVmax above the median value for the study cohort (Table 3). Whether this reflects statistical noise from a small sample or true limitations of SUV-based measures, it is clear that validation of a more robust FDG-PET- defined biomarker could be of considerable clinical value, complementing the incrementally improved staging accuracy of PET-CT.

Metabolic tumor volume is a novel PET-specific measure, which incorporates complementary information relevant to both disease burden (akin to clinical stage and CT-derived tumor volume, which are prognostic for outcomes (25, 26)) and tumor metabolic activity. Although the size of our dataset is limited, our findings add to an emerging literature, which suggests that high primary metabolic tumor volume is associated with local-regional relapse and reduced progression-free survival following radiotherapy.

Despite expected correlation of primary MTV with T stage (15), earlier reports suggest that MTV dominates univariate and multivariate models of treatment outcome, independent of T stage or HPV infection status (16, 17). Interestingly, these same reports also suggest lack of utility for SUV values and nodal MTV. Although formal multivariate analysis was not deemed appropriate due to limited events, the effect of primary MTV was independent of age, gender, Zubrod performance status, pack-years, T stage, and N stage in bivariate analysis. And while elevated primary MTV was strongly associated with regional and distant disease failure in our series, nodal MTV remained non-prognostic. Although tempting to speculate that biology and tissue architecture specific to nodal disease (such as cystic adenopathy seen in HPV-associated disease) confounds productive use of MTV in regional disease sites, this requires follow-up study for definitive characterization. Along this vein, closer correlation of primary MTV with locoregional/distant disease failure than with local failure (Table 4) is in keeping with prior reported data [17], and suggests need for complementary work to mechanistically explain the exact biological significance of primary MTV.

Pretreatment imaging biomarkers can potentially direct personalized treatment intensity. Our findings also suggest that intraobserver PET reading consistency is best in the pretreatment setting. Both issues are of relevance to HPV-associated oropharyngeal disease, which typically responds briskly to treatment and may benefit from pretreatment PET-guided de-intensification strategies to limit toxicity. Seven of 8 oropharyngeal cancer relapses in the PET imaging analysis cohort were p16-positive. These 7 patients suffered recurrences in varied locations: 1 tumor recurred in the primary site, 4 recurred in the neck, 1 recurred locoregionally, and 1 recurred both locoregionally and distantly. Six of these 7 patients had discordant above-median baseline primary MTV values in the face of below-median baseline SUVmax. This spotlights the candidacy of MTV as an imaging-based identifier of "intermediate-risk" p16-positive disease (27, 28) (i.e. HPV-associated oropharynx patients with bulky primary tumor and/or traditional risk-factor exposure history who suffer inferior treatment outcomes and are not appropriate for de-intensified therapy). Nonetheless, this remains an early hypothesis-generating result subject to the potential biases and study power limitations of unplanned subgroup analysis. Formal testing in future multicenter trials is mandatory for validation.

Presence of a strong prognostic signal for MTV in our small, heterogeneous study cohort is encouraging. Nonetheless, MTV has limitations as a candidate imaging biomarker. No standard definition for MTV currently exists. Earlier series have used variable, arbitrarily defined % primary and nodal SUVmax cutoffs to delineate MTV. Accordingly, the relative prognostic performance of specific MTV cutoff values is difficult to compare across published series. In addition, practical use of MTV following treatment is challenging given return of responding tumor sites to background tracer uptake levels. Although prior pilot work supports the use of a post-treatment MTV threshold of SUV = 2.0 (29), this could not be feasibly reproduced in this study with commercially available software. Future confirmatory work remains necessary.

Another key limitation of our findings is that formal participation of patients enrolled onto the RTOG 0522 trial was limited to 116 patients, and that only 74 of these patients had a full complement of serial imaging available for the analysis specified by protocol. While reasons for low participation remain speculative, the resulting small sample size suffers from limited statistical power and potential provider-dependent selection biases. Fortunately, the clinical characteristics of the subgroup match reasonably with those of the eligible population as a whole (Table 1), suggesting broader applicability of our findings to the general head and neck radiotherapy patient population. Similar study power issues also impact our secondary subgroup analysis of p16+ patients.

To conclude, we found a unique prognostic signal for primary tumor FDG-PET-derived MTV in patients with locally advanced head and neck cancer. This finding remains preliminary, and requires technical refinement and clinical confirmation. There is growing need to better match resource-intensive treatment to individual patient risk. Validation of MTV, a straightforward, non-invasive measure derived from routine workup imaging, could be an important step towards accomplishing this goal.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

References

1. Kyzas PA, Evangelou E, Denaxa-Kyza D, Ioannidis JP. 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst. 2008; 100:712–20. [PubMed: 18477804]

2. Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004; 22:4357–68. [PubMed: 15514377]

3. Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med. 2007; 48 (Suppl 1):78S–88S. [PubMed: 17204723]

4. Facey K, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess. 2007; 11:iii–iv. xi–267. [PubMed: 17999839]

5. Syed R, Bomanji JB, Nagabhushan N, Hughes S, Kayani I, Groves A, et al. Impact of combined (18)F-FDG PET/CT in head and neck tumours. Br J Cancer. 2005; 92:1046–50. [PubMed: 15770212]

6. Schoder H, Yeung HW, Gonen M, Kraus D, Larson SM. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology. 2004; 231:65–72. [PubMed: 14990824]

7. Schwartz DL, Ford E, Rajendran J, Yueh B, Coltrera MD, Virgin J, et al. FDG-PET/ CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. International journal of radiation oncology, biology, physics. 2005; 61:129–36.

8. Veit-Haibach P, Luczak C, Wanke I, Fischer M, Egelhof T, Beyer T, et al. TNM staging with FDG-PET/CT in patients with primary head and neck cancer. Eur J Nucl Med Mol Imaging. 2007; 34:1953–62. [PubMed: 17717661]

9. Gregoire V. Is there any future in radiotherapy planning without the use of PET: unraveling the myth. Radiother Oncol. 2004; 73:261–3. [PubMed: 15588868]

10. Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, et al. Prospective imaging assessment of mortality risk after head-and-neck radiotherapy. Int J Radiat Oncol Biol Phys. 2010; 78:667–74. [PubMed: 20171802]

11. Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer. 2002; 86:512–6. [PubMed: 11870529]

12. Allal AS, Dulguerov P, Allaoua M, Haenggeli CA, El-Ghazi el A, Lehmann W, et al. Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol. 2002; 20:1398–404. [PubMed: 11870185]

13. Schwartz DL, Rajendran J, Yueh B, Coltrera MD, Leblanc M, Eary J, et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg. 2004; 130:1361–7. [PubMed: 15611393]

14. Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, et al. Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol. 2009; 27:2509–15. [PubMed: 19332725]

15. Chung MK, Jeong HS, Park SG, Jang JY, Son YI, Choi JY, et al. Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res. 2009; 15:5861–8. [PubMed: 19737951]

16. La TH, Filion EJ, Turnbull BB, Chu JN, Lee P, Nguyen K, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009; 74:1335–41. [PubMed: 19289263]

17. Tang C, Murphy JD, Khong B, La TH, Kong C, Fischbein NJ, et al. Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012; 83:1514–20. [PubMed: 22270174]

18. Kalbfleish, J.; Prentice, R. The statistical analysis of failure time data. New York: John Wiley and Sons; 1980.

19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assoc. 1958; 53:457–81.

20. Cox DR. Regression models and life tables. J Royal Statist Soc. 1972; 34:187–229.

21. Yao M, Graham MM, Hoffman HT, Smith RB, Funk GF, Graham SM, et al. The role of post-radiation therapy FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma. International journal of radiation oncology, biology, physics. 2004; 59:1001–10.

22. Van Buuren S, Brand JPL, Groothuis-Oudshoorn CGM, et al. Fully conditional specification in multivariate imputation. J Stat Comput Sim. 2006; 76:1049–64.

23. Rubin, DB. Multiple imputation for nonresponse in surveys. New York, NY: John Wiley & Sons; 1987.

24. Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control. 1974; 19:716–23.

25. Hermans R, Op de beeck K, Van den Bogaert W, Rijnders A, Staelens L, Feron M, et al. The relation of CT-determined tumor parameters and local and regional outcome of tonsillar cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys. 2001; 50:37–45. [PubMed: 11316544]

26. Lodder WL, Pameijer FA, Rasch CR, van den Brekel MW, Balm AJ. Prognostic significance of radiologically determined neck node volume in head and neck cancer: a systematic review. Oral Oncol. 2012; 48:298–302. [PubMed: 22112442]

27. Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, et al. Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006; 24:736–47. [PubMed: 16401683]

28. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363:24–35. [PubMed: 20530316]

29. Murphy JD, La TH, Chu K, Quon A, Fischbein NJ, Maxim PG, et al. Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011; 80:514–21. [PubMed: 20646870]

SUMMARY

There is need to better match cancer treatment to individual patient risk. Tumor imaging provides a means to define disease phenotype and treatment response. Predefined study objectives of the recently concluded RTOG 0522 trial included correlation of PET/CT findings with treatment outcomes. In this report, we describe a potential prognostic signal for primary tumor FDG-PET-derived MTV in patients with locally advanced head and neck cancer. This finding remains preliminary, and requires further confirmation.

Figure 1.

Cumulative incidence estimates of local-regional relapse (Panel A) and distant metastasis (Panel B) and Kaplan-Meier estimates of progression-free survival (Panel C) and overall survival (Panel D) for patients with baseline primary MTV   median or > median. Two-year local-regional relapse rates were 5.7% (95% CI: 0, 13.5) for patients with MTV   median and 30.3% (95% CI: 14.3, 46.3) for patients with MTV > median. Two-year distant metastases rates were 2.9% (95% CI: 0, 8.5) for patients with MTV   median and 12.1% (95% CI: 0.8, 23.4) for patients with MTV > median. Two-year progression-free survival rates were 88.6% (95% CI: 78.0, 99.1) for patients with MTV   median and 63.6% (95% CI: 47.2, 80.0) for patients with MTV > median. Two-year overall survival rates were 94.3% (95% CI: 86.6, 100) for patients with MTV   median and 84.9% (95% CI: 72.6, 97.1) for patients with MTV > median.

Table 1

Patient Characteristics

	Included in PET/CT study (n=74)	Eligible for PET/CT study but excluded (n=577)
Assigned treatment, p=0.26 [1]		
RT + cisplatin	42 (56.8%)	287 (49.7%)
RT + cisplatin + cetuximab	32 (43.2%)	290 (50.3%)
Age (years), p=1.00 [2]		
Mean (standard deviation)	56.8 (6.67)	56.7 (8.22)
Median (range)	56 (42–73)	57 (34–79)
Gender, p=0.68 [1]		
Male	65 (87.8%)	516 (89.4%)
Female	9 (12.2%)	61 (10.6%)
Zubrod performance status, p=0.03 [1]		
0	58 (78.4%)	380 (65.9%)
1	16 (21.6%)	197 (34.1%)
Smoking history: pack-years, p=0.03 [2]	(n=54)	(n=512)
Mean (standard deviation)	20.8 (29.88)	26.1 (26.96)
Median (range)	8.75 (0–135)	21 (0–162)
Primary site, p=0.72 [1]		
Oropharynx	58 (78.4%)	449 (77.8%)
Hypopharynx	7 (9.5%)	43 (7.5%)
Larynx	9 (12.2%)	85 (14.7%)
p16 status, oropharynx only, p=0.98 [1]	(n=33)	(n=229)
Negative	8 (24.2%)	55 (24.0%)
Positive	25 (75.8%)	174 (76.0%)
T stage, p=0.04 [2]		
T2	29 (39.2%)	303 (52.5%)
T3	26 (35.1%)	157 (27.2%)
T4	19 (25.7%)	117 (20.3%)
N stage, p=0.23 [2]		
N2a	5 (6.8%)	73 (12.7%)
N2b	34 (45.9%)	259 (44.9%)
N2c	29 (39.2%)	207 (35.9%)
N3	6 (8.1%)	38 (6.6%)

[1]Pearson chi-square test.

[2]Wilcoxon rank-sum test.

Table 2

FDG-PET/CT Outcome Measures

Measurement		Intraclass Correlation Coefficient (95% CI)
Pre-treatment primary SUVmax [1]	(n=68)	1.00 (N/A)
Mean (standard deviation)	15.84 (6.68)	
Median (range)	15.07 (3.45 – 40.02)	
Post-treatment primary SUVmax [1,2]	(n=67)	0.93 (0.89, 0.96)
Mean (standard deviation)	4.65 (2.06)	
Median (range)	4.31 (1.75 – 14.48)	
Pre-treatment primary SUVpeak [1]	(n=68)	0.99 (0.98, 0.99)
Mean (standard deviation)	12.68 (6.19)	
Median (range)	11.23 (2.54 – 37.36)	
Post-treatment primary SUVpeak [1,2]	(n=67)	0.83 (0.73, 0.89)
Mean (standard deviation)	3.23 (1.53)	
Median (range)	3.18 (1.28 – 11.78)	
Pre-treatment primary MTV [1]	(n=68)	0.99 (0.98, 0.99)
Mean (standard deviation)	13.80 (12.55)	
Median (range)	8.76 (2.22 – 64.45)	
Pre-treatment nodal SUVmax [1,3]	(n=65)	R: 0.99 (0.98, 0.99)
Mean (standard deviation)	11.62 (6.81)	L: 1.00 (N/A)
Median (range)	10.55 (2.08 – 42.96)	
Post-treatment nodal SUVmax [1,2,3]	(n=62)	R: 0.82 (0.69, 0.90)
Mean (standard deviation)	2.93 (1.20)	L: 0.87 (0.77, 0.93)
Median (range)	2.66 (1.03 – 6.91)	
Pre-treatment nodal SUVpeak [1,3]	(n=65)	R: 0.99 (0.98, 0.99)
Mean (standard deviation)	8.47 (5.00)	L: 1.00 (N/A)
Median (range)	7.73 (1.34 – 27.93)	
Post-treatment nodal SUVpeak [1,2,3]	(n=62)	R: 0.59 (0.34, 0.76)
Mean (standard deviation)	1.97 (0.56)	L: 0.51 (0.23, 0.71)
Median (range)	1.95 (0.73 – 3.90)	
Pre-treatment nodal MTV [1,4]	(n=61)	R: 0.99 (0.98, 0.99)
Mean (standard deviation)	14.38 (18.25)	L: 0.95 (0.91, 0.97)
Median (range)	10.10 (1.46 – 141.01)	
Pre-treatment total MTV [1,5]	(n=60)	
Mean (standard deviation)	27.56 (21.89)	
Median (range)	21.77 (3.85 – 149.64)	

CI: confidence interval; R: right neck; L: left neck; N/A: not applicable.

[1] If both reader values available, mean was used.

[2] Patients that progressed prior to post-treatment PET were excluded.

[3]If bilateral, maximum of right and left sides was used.

[4]If bilateral, sum of right and left sides was used.

[5]Sum of primary and nodal MTV.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3

Correlation of Baseline SUV Values with Treatment Outcomes

Variable	Endpoint	Events/total	Hazard ratio (95% CI)	p-value
Primary SUVmax (> vs. median)	Local relapse	0/34 vs. 8/34	Cannot estimate	
	Local-regional relapse	4/34 vs. 12/34	0.31 (0.10, 0.97)	0.04
	Distant metastasis	2/34 vs. 6/34	0.32 (0.06, 1.57)	0.16
	Progression-free survival	6/34 vs. 18/34	0.30 (0.12, 0.75)	0.01
	Overall survival	4/34 vs. 11/34	0.38 (0.12, 1.20)	0.10
Nodal SUVmax (> vs. median)	Regional relapse	6/32 vs. 7/33	0.89 (0.30, 2.66)	0.84
	Local-regional relapse	6/32 vs. 9/33	0.72 (0.26, 2.05)	0.54
	Distant metastasis	2/32 vs. 5/33	0.40 (0.08, 2.05)	0.27
	Progression-free survival	8/32 vs. 15/33	0.56 (0.24, 1.33)	0.19
	Overall survival	4/32 vs. 10/33	0.44 (0.14, 1.39)	0.16
Primary SUVpeak (> vs. median)	Local relapse	1/34 vs. 7/34	0.15 (0.02, 1.23)	0.08
	Local-regional relapse	6/34 vs. 10/34	0.60 (0.22, 1.65)	0.32
	Distant metastasis	3/34 vs. 5/34	0.62 (0.15, 2.62)	0.52
	Progression-free survival	9/34 vs. 15/34	0.62 (0.27, 1.42)	0.25
	Overall survival	5/34 vs. 10/34	0.55 (0.19, 1.62)	0.28
Nodal SUVpeak (> vs. median)	Regional relapse	6/32 vs. 7/33	0.93 (0.31, 2.77)	0.90
	Local-regional relapse	6/32 vs. 9/33	0.75 (0.27, 2.13)	0.59
	Distant metastasis	3/32 vs. 4/33	0.81 (0.18, 3.63)	0.79
	Progression-free survival	9/32 vs. 14/33	0.74 (0.32, 1.72)	0.49
	Overall survival	5/32 vs. 9/33	0.61 (0.20, 1.82)	0.37

CI = confidence interval.

Hazard ratios estimated from Cox models.

Table 4

Correlation of Baseline Primary MTV with Treatment Outcomes

Variable	Endpoint	Events/total	Hazard ratio (95% CI)	p-value
Primary MTV (continuous)	Local relapse	8/68	1.05 (1.00, 1.09)	0.06
	Local-regional relapse	16/68	1.05 (1.02, 1.08)	<.01
	Distant metastasis	8/68	1.04 (1.01, 1.08)	0.02
	Progression-free survival	24/68	1.05 (1.02, 1.07)	<.01
	Overall survival	15/68	1.03 (1.00, 1.06)	0.08
Primary MTV (> vs. median)	Local relapse	5/33 vs. 3/35	1.96 (0.47, 8.23)	0.36
	Local-regional relapse	12/33 vs. 4/35	4.01 (1.28, 12.52)	0.02
	Distant metastasis	6/33 vs. 2/35	3.62 (0.73, 18.04)	0.12
	Progression-free survival	15/33 vs. 9/35	2.34 (1.02, 5.37)	0.05
	Overall survival	8/33 vs. 7/35	1.40 (0.51, 3.86)	0.52

CI = confidence interval.

Hazard ratios estimated from Cox models.

Table 5

Primary MTV vs. T Stage

Model	AIC [1]	Covariate(s)	Hazard ratio (95% CI)	p-value
Local-regional relapse				
1	120.28	Primary MTV (> vs. median)	4.01 (1.28, 12.52)	0.02
2	124.63	T stage (T4 vs. T2–3)	2.34 (0.83, 6.59)	0.11
3	121.98	Primary MTV (> vs. median) T stage (T4 vs. T2–3)	3.59 (1.07, 12.11) 1.36 (0.45, 4.11)	0.04 0.58
Progression-free survival				
1	183.20	Primary MTV (> vs. median)	2.34 (1.02, 5.37)	0.05
2	186.52	T stage (T4 vs. T2–3)	1.54 (0.63, 3.74)	0.34
3	185.19	Primary MTV (> vs. median) T stage (T4 vs. T2–3)	2.31 (0.94, 5.70) 1.03 (0.39, 2.71)	0.07 0.95

CI = confidence interval.

Hazard ratios estimated from Cox models.

[1] Akaike information criterion.